Abstract
We conclude that HPV types 16/18 infection is frequent in East African patients with AIDS-associated squamous cell carcinoma of the conjunctiva. EGFR activation/alteration may contribute to and sustain the high prevalence of this cancer. Our findings hint that adoption of HPV vaccination strategies may impact the incidence of conjunctival carcinoma. Agents that target the EGFR pathway may have potential therapeutic benefit.
Introduction
In East Africa, the incidence of Conjunctival Squamous Cell Carcinoma (CSCC) has risen dramatically, particularly among individuals living with HIV. While the association with immunosuppression is well-documented, the specific molecular drivers of these aggressive ocular tumors have remained largely unknown. This study investigates two critical factors: the role of high-risk Human Papillomavirus (HPV) as a viral co-factor and the activation of the Epidermal Growth Factor Receptor (EGFR) signaling pathway. Understanding these mechanisms is essential for developing effective prevention and treatment strategies in a region where current options are limited.
Methods and Materials
The research team analyzed 38 formalin-fixed paraffin-embedded (FFPE) tissue specimens obtained from HIV-positive patients at the Uganda Cancer Institute and Kenyatta National Hospital. The samples represented a clinical spectrum of disease: 5 cases of dysplasia, 22 cases of in situ disease, and 11 cases of invasive tumor.
To ensure high-resolution molecular analysis, the following techniques were employed:
- Laser Capture Microdissection (LCM): Used to isolate specific tumor cell populations, minimizing contamination from surrounding healthy tissue.
- Quantitative PCR (qPCR): Utilized for sensitive HPV genotyping (targeting types 16, 18, 52, and 59) and for quantifying EGFR mRNA expression levels.
- Immunohistochemistry (IHC): Performed to visualize the expression and subcellular localization of activated proteins within the EGFR pathway, specifically p-EGFR, p-MAPK, and p-Akt.
- DNA Sequencing: Exons 18–21 of the EGFR gene were sequenced to identify potential mutations within the tyrosine kinase domain.
Results
Viral Etiology
The study identified a high prevalence of high-risk HPV types. HPV 18 was the most frequent, appearing in 61% of the samples. Additionally, 16% of the patients were co-infected with both HPV 16 and 18. This high frequency suggests that HPV is a significant co-factor in the development of CSCC in this population.
EGFR Pathway Activation
A strong correlation was observed between EGFR expression and the severity of the disease ($p = 0.01$). Notably, phosphorylated EGFR (p-EGFR) was found in the cell nucleus exclusively in invasive tumors, suggesting that nuclear translocation may be a critical step in malignant progression.
Furthermore, the activation of downstream signaling molecules, p-MAPK and p-Akt, significantly correlated with tumor invasiveness ($p = 0.05$ and $p = 0.028$, respectively). This indicates that the EGFR pathway is not only overexpressed but actively signaling to promote tumor growth and invasion.
Genetic Alterations
Genetic analysis revealed that patients with measurable EGFR expression were significantly more likely to harbor mutations or Single Nucleotide Polymorphisms (SNPs) within the EGFR gene (35.3% vs. 0%). One missense mutation and several SNPs were identified in the tyrosine kinase domain, providing a genetic basis for the observed receptor overactivity.
Discussion and Conclusion
The findings of this study highlight the dual role of viral infection and molecular signaling in East African CSCC. The high prevalence of HPV 16 and 18 suggests that the implementation of HPV vaccination programs could significantly impact the incidence of this cancer.
Moreover, the clear involvement of the EGFR pathway identifies a potential therapeutic target. EGFR inhibitors, which are already standard of care for other epithelial malignancies, should be evaluated in clinical trials for patients with advanced CSCC. While the study is limited by its retrospective nature and sample size ($n=38$), it provides a compelling molecular rationale for new public health and clinical interventions in the management of conjunctival carcinoma in HIV-infected populations.
Summary updated